Gene · 5819
Papers2,573
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
301 to 320 of 2,573
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Ewing Sarcoma Single-cell Transcriptome Analysis Reveals Functionally Impaired Antigen-presenting Cells. | Cancer Res Commun | 2023 | 37823774 | PubTator, text mining | PubMed |
| Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design. | iScience | 2023 | 37810241 | PubTator, text mining | PubMed |
| Vaccination Against Pneumonia May Provide Genotype-Specific Protection Against Alzheimer's Disease. | J Alzheimers Dis | 2023 | 37807778 | PubTator, text mining | PubMed |
| Comprehensive immunophenotyping of solid tumor-infiltrating immune cells reveals the expression characteristics of LAG-3 and its ligands. | Front Immunol | 2023 | 37795090 | PubTator, text mining | PubMed |
Interactions of Indoleamine 2,3-dioxygenase-expressing LAMP3+ dendritic cells with CD4+ regulatory T cells and CD8+ exhausted T cells: synergistically remodeling of the immunosuppressive microenvironment in cervical cancer and therapeutic implications. | Cancer Commun (Lond) | 2023 | 37794698 | PubTator, text mining | PubMed |
| C5aR1 blockade reshapes immunosuppressive tumor microenvironment and synergizes with immune checkpoint blockade therapy in high-grade serous ovarian cancer. | Oncoimmunology | 2023 | 37791232 | PubTator, text mining | PubMed |
| Exploring the dynamic interplay between cancer stem cells and the tumor microenvironment: implications for novel therapeutic strategies. | J Transl Med | 2023 | 37784157 | PubTator, text mining | PubMed |
| Laminin 332 expression levels predict clinical outcomes and chemotherapy response in patients with pancreatic adenocarcinoma. | Front Cell Dev Biol | 2023 | 37779898 | PubTator, text mining | PubMed |
| Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapies. | Transl Oncol | 2023 | 37776617 | PubTator, text mining | PubMed |
| Multiomic prediction of therapeutic targets for human diseases associated with protein phase separation. | Proc Natl Acad Sci U S A | 2023 | 37774095 | PubTator, text mining | PubMed |
| When Bacteria and Viruses Collide: A Tale of Chlamydia trachomatis and Sexually Transmitted Viruses. | Viruses | 2023 | 37766360 | PubTator, text mining | PubMed |
| Genetic Landscape of Masticatory Muscle Tendon-Aponeurosis Hyperplasia. | Genes (Basel) | 2023 | 37761858 | PubTator, text mining | PubMed |
| Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 Pathway in Advanced, Recurrent Endometrial Cancer: A Scoping Review with SWOT Analysis. | Cancers (Basel) | 2023 | 37760602 | PubTator, text mining | PubMed |
| Dysregulation of DNAM-1-Mediated NK Cell Anti-Cancer Responses in the Tumor Microenvironment. | Cancers (Basel) | 2023 | 37760586 | PubTator, text mining | PubMed |
| Update in Immunotherapy for Advanced Non-Small Cell Lung Cancer: Optimizing Treatment Sequencing and Identifying the Best Choices. | Cancers (Basel) | 2023 | 37760516 | PubTator, text mining | PubMed |
| Palmitic Acid Upregulates CD96 Expression to Mediate Maternal-Foetal Interface Immune Tolerance by Inhibiting Cytotoxic Activity and Promoting Adhesion Function in Human Decidual Natural Killer Cells. | Bioengineering (Basel) | 2023 | 37760110 | PubTator, text mining | PubMed |
| Natural killer cells and their exosomes in viral infections and related therapeutic approaches: where are we? | Cell Commun Signal | 2023 | 37749597 | PubTator, text mining | PubMed |
| Polo-like kinase 1 suppresses lung adenocarcinoma immunity through necroptosis. | Oncol Res | 2023 | 37744268 | PubTator, text mining | PubMed |
| A critical review on antiviral peptides derived from viral glycoproteins and host receptors to decoy herpes simplex virus. | Microb Biotechnol | 2023 | 37740682 | PubTator, text mining | PubMed |
| The role of bone marrow microenvironment (BMM) cells in acute myeloid leukemia (AML) progression: immune checkpoints, metabolic checkpoints, and signaling pathways. | Cell Commun Signal | 2023 | 37735675 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5819/papers?page=16